title: Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A1 chieve study.
abstract: OBJECTIVE
  To determine the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) therapy in the Indian patients with type 2 diabetes previously on basal or basal-bolus insulin therapies.
  
  
  METHODS
  Patients switching from insulin glargine, neutral protamine Hagedorn (NPH) insulin, or basal-bolus insulin to BIAsp 30 in the Indian cohort of the A1 chieve study were included. Safety and efficacy of treatment was evaluated over 24 weeks.
  
  
  RESULTS
  A total of 422 patients (pre-study basal-bolus insulin, 49; NPH insulin, 157; insulin glargine, 216) switched to BIAsp 30. Pre-study insulin doses were 0.61 ± 0.26 U/kg, 0.34 ± 0.2 U/kg and 0.40 ± 0.21 U/kg and the mean week 24 BIAsp 30 doses were 0.50 ± 0.21 U/kg, 0.35 ± 0.15 U/kg and 0.42 ± 0.16 U/kg in the prior basal-bolus insulin, NPH insulin and insulin glargine groups, respectively. No serious adverse drug reactions, major or nocturnal hypoglycemia were reported. The proportion of patients experiencing overall hypoglycemia was significantly lower from baseline (5.6%) to week 24 (1.0%) in the pre-study insulin-glargine group and appeared to be lower in pre-study NPH insulin and basal-bolus insulin groups. Glycemic control improved significantly from baseline week 24 in the pre-study NPH insulin and insulin-glargine groups (P < 0.001), while it appeared to improve in the pre-study basal-bolus group. Quality of life was positively impacted after 24 weeks in all 3 groups.
  
  
  CONCLUSIONS
  The switch from basal or basal-bolus insulin to BIAsp 30 was safe, well tolerated and improved the glycemic control in this Indian cohort.
authors.affiliation: Department of Endocrinology and Metabolism, Manipal Hospitals, Bangalore, Karnataka, India.
authors.forename: Arpandev
authors.initials: A
authors.lastname: Bhattacharyya
authors.affiliation: Novo Nordisk India Private Limited, Bangalore, Karnataka, India.
authors.forename: Raman
authors.initials: R
authors.lastname: Shetty
authors.affiliation: Novo Nordisk India Private Limited, Bangalore, Karnataka, India.
authors.forename: C
authors.initials: C
authors.lastname: Rajkumar
authors.affiliation: Department of Endocrinology, St. John's Medical College and Hospital, Bangalore, Karnataka, India.
authors.forename: Ganapathi
authors.initials: G
authors.lastname: Bantwal
keywords: Basal-bolus insulin; basal insulin; biphasic insulin aspart 30